BioSpace News Archive

Boundless Bio today announced the appointment of two new members to its Board of Directors and the establishment of its Clinical Advisory Board.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck ® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the JonesTrading 2023 Healthcare Summit taking place October 9 - 11 at the Eden Roc hotel in Miami, Florida.

UL Solutions Inc. (the “Issuer”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to a proposed secondary offering by UL Standards & Engagement, the nonprofit organization that is currently the sole stockholder of the Issuer, of Class A common stock of the Issuer.

Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued a complete response letter for the lebrikizumab biologic license application for the treatment of moderate-to-severe atopic dermatitis.

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced that Jeff Mathiesen, Chief Financial Officer, will participate at two upcoming conferences.

Cabaletta Bio, Inc. (Nasdaq: CABA) today announced that the Company’s third Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been allowed to proceed by the U.S. Food and Drug Administration (FDA) for a Phase 1/2 study in patients with systemic sclerosis (SSc).

Nanoscope Therapeutics Inc. is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place in Amsterdam, The Netherlands.

Allarity Therapeutics, Inc. is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023.

Eledon Pharmaceuticals, Inc. announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.